Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC von Deurloo, R., Colombo, N., Mendiola, C., Selle, F., Korach, J., Oestergaard, M.Z., Bylesjo, M., Urban, H-J., Ghazi, Y., Oza, A.

Volltext

TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA von Bolen, C.R., Hiddemann, W., Marcus, R., Herold, M., Huet, S., Salles, G., Mattiello, F., Nielsen, T., Mir, F., Venstrom, J.M., Oestergaard, M.Z.

Volltext

S100 TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA von Bolen, C., Hiddemann, W., Marcus, R., Herold, M., Huet, S., Salles, G., Mattiello, F., Nielsen, T., Mir, F., Venstrom, J. M., Oestergaard, M.Z.

Volltext

CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY von Klanova, M., Sehn, L.H., Bence‐Bruckler, I., Cavallo, F., Jin, J., Martelli, M., Stewart, D., Vitolo, U., Zaja, F., Zhang, Q., Mattiello, F., Oestergaard, M.Z., Fingerle‐Rowson, G.R., Nielsen, T., Trneny, M.

Volltext

PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY von Sehn, L.H., Oestergaard, M.Z., Trněný, M., Bosi, A., Egyed, M., Illes, A., Nakamae, H., Opat, S., Topp, M., Zaja, F., Fingerle‐Rowson, G., Lei, G., Nielsen, T., Punnoose, E.A., Rahman, M., Ray, J., Zhang, L., Martelli, M., Vitolo, U.

Volltext